Cyril Allouche, Principal Accounting Officer at Revance Therapeutics, Inc. (RVNC), sold 750 shares at $15.48 ($12K) on 2019-03-18, disclosed to the SEC on 2019-03-19.
Scheduled sale ($12k) by Principal Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $15.45 | 252 | $4K | 33.6% |
| 2 | $15.48 | 498 | $8K | 66.4% |
| Total | $15.47 avg | 750 | $12K | 100% |
| Filing → |
| RVNC | SELL | 2018-11-21 | $10K | — | Filing → |
| RVNC | SELL | 2018-11-09 | $104K | — | Filing → |
| RVNC | SELL | 2018-07-06 | $11K | — | Filing → |